"Nitriles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE.
| Descriptor ID |
D009570
|
| MeSH Number(s) |
D02.626
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Nitriles".
Below are MeSH descriptors whose meaning is more specific than "Nitriles".
This graph shows the total number of publications written about "Nitriles" by people in this website by year, and whether "Nitriles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 2 | 1 | 3 |
| 1996 | 1 | 2 | 3 |
| 1997 | 3 | 2 | 5 |
| 1998 | 4 | 1 | 5 |
| 1999 | 3 | 1 | 4 |
| 2000 | 2 | 2 | 4 |
| 2001 | 7 | 3 | 10 |
| 2002 | 8 | 5 | 13 |
| 2003 | 10 | 8 | 18 |
| 2004 | 9 | 9 | 18 |
| 2005 | 7 | 7 | 14 |
| 2006 | 8 | 7 | 15 |
| 2007 | 5 | 6 | 11 |
| 2008 | 9 | 8 | 17 |
| 2009 | 0 | 4 | 4 |
| 2010 | 6 | 11 | 17 |
| 2011 | 8 | 19 | 27 |
| 2012 | 7 | 18 | 25 |
| 2013 | 9 | 24 | 33 |
| 2014 | 7 | 18 | 25 |
| 2015 | 9 | 22 | 31 |
| 2016 | 6 | 18 | 24 |
| 2017 | 7 | 23 | 30 |
| 2018 | 4 | 21 | 25 |
| 2019 | 5 | 14 | 19 |
| 2020 | 5 | 14 | 19 |
| 2021 | 10 | 8 | 18 |
| 2022 | 0 | 19 | 19 |
| 2023 | 1 | 16 | 17 |
| 2024 | 11 | 12 | 23 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nitriles" by people in Profiles.
-
Can Ruxolitinib Crash TET2- and IDH2-Driven Clonal Hematopoiesis? Cancer Discov. 2024 Oct 04; 14(10):1768-1770.
-
Janus kinase inhibitor monotherapy and combination therapies for myelofibrosis: what's the current standard of care? Expert Rev Hematol. 2024 Nov; 17(11):769-780.
-
Momelotinib for the treatment of myelofibrosis. Blood. 2024 08 15; 144(7):708-713.
-
Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature. Expert Opin Pharmacother. 2024 Jul; 25(10):1391-1404.
-
ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer. Nucleic Acids Res. 2024 Jul 22; 52(13):7740-7760.
-
Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia. Ann Hematol. 2024 Sep; 103(9):3429-3442.
-
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial. JAMA Netw Open. 2024 Jul 01; 7(7):e2419966.
-
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness". Cell Rep Med. 2024 Jun 18; 5(6):101595.
-
A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial. Haematologica. 2024 06 01; 109(6):1977-1983.
-
Glycyrrhizic acid conjugates with amino acid methyl esters target the main protease, exhibiting antiviral activity against wild-type and nirmatrelvir-resistant SARS-CoV-2 variants. Antiviral Res. 2024 07; 227:105920.